Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
504.50    -0.50 (-0.10%)
Bid:
502.00
Ask:
503.00
Spread: 1.00 (0.199%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

23 Jul 2020 07:00

RNS Number : 8095T
Tate & Lyle PLC
23 July 2020
 

23 July 2020 - Tate & Lyle PLC

 

 

TRADING STATEMENT

 

Tate & Lyle issues the following trading statement for the three months to 30 June 2020.

 

As anticipated in our trading update on 4 May 2020 and in our full-year results statement on 21 May 2020, the Group's performance in the first quarter reflected the impact of lockdowns on out-of-home consumption in North America and Europe, partially offset by resilience from in-home consumption. Having seen fluctuating demand patterns in April and May, demand improved in both divisions in June as lockdowns started to ease. The full extent of the pandemic's impact still remains unclear.

 

Our response to Covid-19 has successfully focused on ensuring we look after the health, safety and wellbeing of our colleagues, their families and the local communities in which we operate; and to work closely with our customers to play our part in supporting the food supply chain with all our manufacturing facilities remaining fully operational in the quarter.

 

Three months ended 30 June 2020

Volume change

Revenue growth*

 

Food & Beverage Solutions

 

(2%)

 

+1% 

Sucralose

(2%)

(1%)

Primary Products

(12%)

(9%)

 

 

 

Group

 

(5%)

 

* Growth in constant currency

 

Food & Beverage Solutions

Revenue was £232 million, 1% higher benefiting from good price and mix management and 9% growth in New Products[1] revenue. Volume was 2% lower as reduced demand for ingredients used in food and drink consumed out-of-home (representing 15% to 25% of revenue) outweighed stronger demand for packaged and shelf-stable foods for consumption in-home.

 

In North America, revenue for the quarter was 2% lower due to reduced demand for out-of-home consumption particularly in the food service sector. North America returned to revenue growth in June as lockdown restrictions eased. In Europe, Middle East and Africa revenue was in line with the comparative period reflecting solid demand for in-home consumption. In Asia Pacific and Latin America revenue was 8% higher reflecting good revenue growth in Asia Pacific as China emerged from lockdown, while in Latin America revenue grew modestly, slowing as the quarter progressed and the region went into lockdown.

 

Sucralose

Revenue was £39 million, 1% lower reflecting softer demand for products consumed out-of-home, particularly beverages.

 

Primary Products

Revenue was £420 million, 9% lower. North American bulk sweetener volume was 12% lower reflecting reduced out-of-home consumption (representing around 30% of sweetener consumption) with demand recovering sequentially during the quarter as some US states began to ease lockdown restrictions. Industrial starch volume was 16% lower as the paper industry took actions to reduce capacity temporarily with many schools and offices still closed.

 

Reducing costs and preserving cash

The financial impact of lower demand was partially mitigated by actions taken to reduce costs including freezing salary increases and recruitment and significantly reducing discretionary costs. Procedures were also put in place to preserve cash through re-prioritising capital commitments and a rigorous approach to managing working capital. No employees have been furloughed and no government aid has been sought.

 

Strong balance sheet

Our balance sheet is strong with net debt at 30 June 2020 of £384 million, £67 million lower than at 31 March 2020 reflecting seasonal improvement and good cash management.

 

Nick Hampton, Chief Executive said:

"As expected, the first quarter presented many challenges and I am very proud of the way we are navigating the impact of Covid-19. We are encouraged by the improvement in demand we saw in June and the continued strategic progress we are making, with new product revenue growing 9% in the quarter. Our new business pipeline is healthy, we continue to find creative ways to use technology to support and connect with our customers, and all our manufacturing facilities remain fully operational.

 

The fundamentals of our business are sound. Demand for ingredients and solutions which enable consumers to enjoy healthier and tastier food and drink is strong, and we have the portfolio of products and technical expertise to help our customers deliver on these trends.

 

Looking ahead, our priorities are clear - to look after our people and communities, strengthen our relationships with customers, continue to progress our strategy and maintain our financial strength. I am confident that our future prospects remain strong."

 

 

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Nick Hasell, FTI Consulting (Media)

Tel: Mobile: +44 (0) 7825 523 383

 

 

About Tate & Lyle:

Tate & Lyle is a global provider of solutions and ingredients for food, beverage and industrial markets.

Tate & Lyle operates through two global divisions, Food & Beverage Solutions and Primary Products, supported by the Innovation and Commercial Development and Global Operations teams. Food & Beverage Solutions is focused on growth by building leading positions globally in the categories of beverages, dairy, and soups, sauces and dressings. Primary Products is focused on delivering steady earnings and generating cash.

Food & Beverage Solutions consists of: Texturants, including speciality starches; Sweeteners, including low- and no-calorie sweeteners; and a Health and Wellness portfolio comprising mainly speciality fibres; and Stabilisers and Functional Systems, which are bespoke ingredient blends that ensure foods retain their structure.

Primary Products consists of high-volume sweeteners, industrial starches and fermentation products (primarily acidulants). It also sells co-products from the corn milling process as animal nutrition.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2020, Tate & Lyle revenue totalled £2.9 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter or LinkedIn.

 

 

 

[1] New Products are products launched in the last seven years

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKKBBKABKDFOB
Date   Source Headline
15th May 202611:53 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
15th May 202611:35 amRNSForm 8.5 (EPT/RI)-Tate & Lyle plc
15th May 202611:29 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
15th May 202611:28 amBUSForm 8.3 - TATE & LYLE PLC
15th May 202611:25 amRNSForm 8.3 - Tate & Lyle PLC
15th May 202611:20 amRNSForm 8.5 (EPT/NON-RI)-Tate & Lyle plc
15th May 202611:09 amRNSForm 8.3 - Tate & Lyle plc
15th May 202611:06 amRNS20260514_TATE & LYLE_8.5 EPT NON-RI_UK_BOFASE
15th May 202611:04 amRNS20260514_TATE & LYLE_8.5 EPT RI_UK_MLI
15th May 202610:56 amRNSForm 8.3 Tate & Lyle PLC
15th May 202610:49 amPRNForm 8.3 - Tate & Lyle PLC
15th May 202610:24 amBUSDimensional Fund Advisors Ltd. : Form 8.3 - TATE & LYLE PLC - Ordinary Shares
15th May 20268:56 amRNSForm 8.5 (EPT/RI)
14th May 20264:15 pmRNSPossible 595 pence all-cash offer for Tate & Lyle
14th May 20263:25 pmRNSForm 8.3 - Tate & Lyle plc
14th May 20261:24 pmRNSDisclosure Table
14th May 20261:07 pmRNSStatement re Possible Offer for Tate & Lyle
1st May 202610:00 amRNSTotal Voting Rights
1st Apr 20264:00 pmRNSHolding(s) in Company
27th Mar 20262:00 pmRNSHolding(s) in Company
13th Mar 20264:00 pmRNSHolding(s) in Company
2nd Mar 20262:00 pmRNSHolding(s) in Company
26th Feb 20267:00 amRNSTrading Statement
23rd Feb 202610:00 amRNSHolding(s) in Company
17th Feb 202612:00 pmRNSHolding(s) in Company
21st Jan 20267:00 amRNSDirectorate change
15th Jan 20269:00 amRNSHolding(s) in Company
12th Jan 202610:00 amRNSHolding(s) in Company
7th Jan 20264:30 pmRNSDirector/PDMR Shareholding
7th Jan 20262:30 pmRNSBlock listing Interim Review
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
11th Dec 202512:18 pmRNSDirector/PDMR Shareholding
9th Dec 20259:00 amRNSHolding(s) in Company
27th Nov 202510:00 amRNSDirector/PDMR Shareholding
11th Nov 20254:30 pmRNSDirector/PDMR Shareholding
10th Nov 20252:40 pmRNSDirector Declaration
6th Nov 20257:00 amRNSHalf-year Financial Report
5th Nov 20252:15 pmRNSHolding(s) in Company
3rd Nov 20255:00 pmRNSHolding(s) in Company
29th Oct 20252:00 pmRNSHolding(s) in Company
23rd Oct 20254:15 pmRNSHolding(s) in Company
21st Oct 20253:30 pmRNSHolding(s) in Company
16th Oct 202512:00 pmRNSHolding(s) in Company
8th Oct 202512:00 pmRNSHolding(s) in Company
6th Oct 20254:30 pmRNSDirector/PDMR Shareholding
6th Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 202510:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSPre-close statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.